您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > D,L-Buthionine-(S,R)-sulfoximine hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
D,L-Buthionine-(S,R)-sulfoximine hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
D,L-Buthionine-(S,R)-sulfoximine hydrochloride图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
50mg电议
100mg电议
200mg电议

产品介绍
D,L-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) 是谷氨酰半胱氨酸合成酶生物合成的有效抑制剂。
别名Buthionine sulfoximine hydrochloride; BSO hydrochloride
Canonical SMILESOC(C(N)CCS(CCCC)(=N)=O)=O.[H]Cl
分子式C8H19ClN2O3S
分子量258.77
溶解度Water: ≥ 140 mg/mL (541.02 mM); DMSO: ≥ 125 mg/mL (483.05 mM); Ethanol: 25 mg/mL (96.61 mM)
储存条件4°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

D,L-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis. Glutamylcysteine synthetase[1]

Buthionine sulfoximine is an analogs of methionine sulfoximine and inhibits gamma-glutamylcysteine synthetase about 20 times more effectively than prothionine sulfoximine and at least 100 times more effectively than methionine sulfoximine[1].

Treatment of mice bearing HT1080 and HT1080/DR4 xenografts with a continuous i.v infusion of nontoxic doses of D,L-Buthionine-(S,R)-sulfoximine (300 and 600 mg/kg/day) produce a 60% reduction of GSH plasma levels and greater than 95 % reduction in GSH tumor levels in both parental and multidrug-resistant tumors[2].

[1]. Griffith OW, et al. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979 Aug 25;254(16):7558-60. [2]. Vanhoefer U, et al. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996 Dec;2(12):1961-8.